Aratana Therapeutics Inc Hits New 52-Week High at $16.46 (PETX)
Shares of Aratana Therapeutics (NASDAQ:PETX) hit a new 52-week high during trading on Thursday, AR Network reports. The stock traded as high as $16.46 and last traded at $15.64, with a volume of 209,143 shares trading hands. The stock had previously closed at $15.09.
Several analysts have recently commented on the stock. Analysts at William Blair initiated coverage on shares of Aratana Therapeutics (NASDAQ:PETX) in a research note to investors on Tuesday, July 23rd. They set an “outperform” rating on the stock. Separately, analysts at Lazard Capital Markets initiated coverage on shares of Aratana Therapeutics (NASDAQ:PETX) in a research note to investors on Tuesday, July 23rd. They set a “buy” rating and a $28.00 price target on the stock. Finally, analysts at Craig Hallum initiated coverage on shares of Aratana Therapeutics (NASDAQ:PETX) in a research note to investors on Monday, July 22nd. They set a “buy” rating on the stock.
Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $19.00.
Aratana Therapeutics has a one year low of $6.56 and a one year high of $16.06. The stock has a 50-day moving average of $9.87 and a 200-day moving average of $9.55. The company’s market cap is $348.3 million.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($4.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($10.21) by $5.59. On average, analysts predict that Aratana Therapeutics will post $-2.80 earnings per share for the current fiscal year.
Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.